...
By Elliot Anderson and Roger Klein
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
There was a time when health services research asked hard, practical questions without delving into politics and presuming to address social—not medical—issues. For decades, the Agency for Healthcare Research and Quality (AHRQ) funded studies on quality, safety, efficiency, and effectiveness. Although these efforts were often technical and ponderous to read, they were grounded in evidence that clinicians and policymakers could actually use.
That “classic AHRQ” model unraveled after 2015. Equity and DEI, once secondary analytic lenses, became central organizing principles. Funding announcements increasingly demanded that research advance equity, reduce disparities, and center on marginalized populations—often before demonstrating measurable improvements in care. Scientific neutrality gave way to moral signaling.
Under the Biden administration, this shift accelerated and hardened into formal policy. AHRQ issued Special Emphasis Notices calling for research explicitly “to advance health equity” and address “structural and systemic inequities.” Dissemination and implementation funding announcements required applicants to demonstrate how projects would reduce disparities, engage community partners, and prioritize “historically underserved populations,” frequently elevating these criteria alongside—or above—traditional measures of effectiveness.
Read More on Opinion
...
In dissemination and implementation, grant solicitations for Patient-Centered Outcomes Research (PCOR)—which is intended to address the comparative clinical effectiveness of two or more preventive, diagnostic, treatment, or health care delivery approaches—applicants were instructed to embed equity frameworks into study design, governance, and evaluation. Success was defined not only by whether evidence-based interventions improved outcomes, but by whether they achieved “equitable reach,” “inclusive engagement,” and alignment with equity goals. Metrics such as participation, representation, and process fidelity often took precedence over clinical endpoints.
This was not a marginal change in emphasis. It was a redefinition of what counted as fundable science.
Research proposals were increasingly expected to foreground concepts such as structural racism, systemic inequity, and social determinants of health. Studies that asked narrower questions—about comparative effectiveness, cost tradeoffs, or unintended consequences—found themselves competing at a disadvantage if they could not be framed within the prevailing equity narrative. Evidence that failed to support that narrative struggled to gain traction.
AHRQ’s change in focus was not an evolution of the agency’s mission; it was a distortion of it.
AHRQ’s statutory charge is not to adjudicate social justice debates. It is to generate evidence that improves how health care is delivered. That mission assumes disagreement, tradeoffs, and the possibility that well-intentioned interventions fail. It leaves room for negative results and inconvenient findings. The Biden-era approach narrowed that space, substituting aspirational frameworks for empirical uncertainty.
AHRQ’s approach under the Trump Administration marks a sharp break with the Biden era. Stated priorities emphasize a modernized return to AHRQ’s historic role: rigorous methods, replication, chronic disease, artificial intelligence tools, and stewardship of public funds. Equity and DEI are longer driving the AHRQ paradigm. Rather, AHRQ is focusing on improving health outcomes for all Americans.
This reset has unsettled many in the health services research community, particularly those whose careers advanced during the equity-first era. But elections have consequences. Discomfort on the part of DEI advocates is a positive sign that AHRQ is helping to advance the mandate voters gave to President Trump.
Classic AHRQ did not ignore differences in the quality of and access of Americans to health services. Instead, it studied them—often carefully and skeptically—without presuming solutions. It allowed for findings that contradicted leftist policy dogma, valued a thoughtful, measured approach, and enforced methodological rigor. In contrast, AHRQ’s new approach has increasingly rewarded alignment over inquiry and consensus over critique. The Trump era represents AHRQ’s abandonment of “woke” advocacy and its return to its role as an independent evaluator of the health care system.
Elliot Anderson is Confidential Assistant to the Director at AHRQ.
Roger Klein is Director of AHRQ.
The views expressed in this article are the writers' own.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines